Relative Bioavailability of HTL0018318 Oral Aqueous Solution Versus Capsules
- First Posted Date
- 2016-11-08
- Last Posted Date
- 2017-02-03
- Lead Sponsor
- Heptares Therapeutics Limited
- Target Recruit Count
- 37
- Registration Number
- NCT02958696
- Locations
- 🇬🇧
Hammersmith Medicines Research, London, United Kingdom
Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-03-16
- Last Posted Date
- 2016-10-18
- Lead Sponsor
- Heptares Therapeutics Limited
- Target Recruit Count
- 14
- Registration Number
- NCT02710188
- Locations
- 🇬🇧
Quotient Clinical, Ruddington, Nottingham, United Kingdom
Phase 1 Study Investigating Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-09-10
- Last Posted Date
- 2017-02-03
- Lead Sponsor
- Heptares Therapeutics Limited
- Target Recruit Count
- 54
- Registration Number
- NCT02546310
- Locations
- 🇬🇧
Neuroscience and Psychiatry Unit, Manchester, United Kingdom
Phase I, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of an M1 Agonist to Treat Cognitive Impairment
- First Posted Date
- 2014-11-14
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Heptares Therapeutics Limited
- Target Recruit Count
- 108
- Registration Number
- NCT02291783
- Locations
- 🇬🇧
Parexel Early Phase Clinical Unit, Harrow, Middlesex, United Kingdom
© Copyright 2024. All Rights Reserved by MedPath